A CDKN2A mutation in familial melanoma that abrogates binding of p16INK4a to CDK4 but not CDK6

被引:42
|
作者
Jones, Rebecca
Ruas, Margarida
Gregory, Fiona
Moulin, Stephanie
Delia, Domenico
Manoukian, Siranoush
Rowe, Janice
Brookes, Sharon
Peters, Gordon [1 ]
机构
[1] CRUK London Res Inst, Mol Oncol Lab, London WC2A 3PX, England
[2] Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy
关键词
D O I
10.1158/0008-5472.CAN-07-1528
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The CDKN2A locus encodes two distinct proteins, p16(INK4a) and pI4(ARF), both of which are implicated in replicative senescence and tumor suppression in different contexts. Here, we describe the characterization of a novel strain of human diploid fibroblasts (designated Milan HDFs) from an individual who is homozygous for the R24P mutation in p16(INK4a) As this mutation occurs in the first exon of INK4a (exon 1 alpha), it has no effect on the primary sequence of p14(ARE). Based on both in vitro and in vivo analyses, the R24P variant is specifically defective for binding to CDK4 but remains able to associate with CDK6. Nevertheless, Milan HDFs behave as if they are p16(INK4a) deficient, in terms of sensitivity to spontaneous and oncogene-induced senescence, and the R24P variant has little effect on proliferation when ectopically expressed in normal fibroblasts. It can, however, impair the proliferation of U20S cells, presumably because they express more CDK6 than primary fibroblasts. These observations suggest that CDK4 and CDK6 are not functionally redundant and underscore the importance of CDK4 in the development of melanoma.
引用
收藏
页码:9134 / 9141
页数:8
相关论文
共 50 条
  • [31] Comprehensive mutational analysis of CDKN2A and CDK4 in Greek patients with cutaneous melanoma
    Nikolaou, V.
    Kang, X.
    Stratigos, A.
    Gogas, H.
    Latorre, M. C.
    Gabree, M.
    Plaka, M.
    Njauw, C. N.
    Kypreou, K.
    Mirmigi, I.
    Stefanaki, I.
    Tsao, H.
    BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 (06) : 1219 - 1222
  • [32] Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/CDKN2A
    Javier Martin-Broto
    Jeronimo Martinez-Garcia
    David S. Moura
    Andres Redondo
    Antonio Gutierrez
    Antonio Lopez-Pousa
    Javier Martinez-Trufero
    Isabel Sevilla
    Roberto Diaz-Beveridge
    Maria Pilar Solis-Hernandez
    Amancio Carnero
    Marco Perez
    David Marcilla
    Jesus Garcia-Foncillas
    Pablo Romero
    Javier Fernandez-Jara
    Daniel Lopez-Lopez
    Ivan Arribas
    Nadia Hindi
    Signal Transduction and Targeted Therapy, 8
  • [33] Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/CDKN2A
    Martin-Broto, Javier
    Martinez-Garcia, Jeronimo
    Moura, David S.
    Redondo, Andres
    Gutierrez, Antonio
    Lopez-Pousa, Antonio
    Martinez-Trufero, Javier
    Sevilla, Isabel
    Diaz-Beveridge, Roberto
    Solis-Hernandez, Maria Pilar
    Carnero, Amancio
    Perez, Marco
    Marcilla, David
    Garcia-Foncillas, Jesus
    Romero, Pablo
    Fernandez-Jara, Javier
    Lopez-Lopez, Daniel
    Arribas, Ivan
    Hindi, Nadia
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)
  • [34] Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds
    José F Flores
    Pamela M Pollock
    Graeme J Walker
    J Michael Glendening
    Amy H-T Lin
    Jane M Palmer
    Marilyn K Walters
    Nicholas K Hayward
    Jane W Fountain
    Oncogene, 1997, 15 : 2999 - 3005
  • [35] Functional availability of γ-herpesvirus K-cyclin is regulated by cellular CDK6 and p16INK4a
    Yoshioka, Hidenori
    Noguchi, Kohji
    Katayama, Kazuhiro
    Mitsuhashi, Junko
    Yamagoe, Satoshi
    Fujimuro, Masahiro
    Sugimoto, Yoshikazu
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2010, 394 (04) : 1000 - 1005
  • [36] Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds
    Flores, JF
    Pollock, PM
    Walker, GJ
    Glendening, JM
    Lin, AHT
    Palmer, JM
    Walters, MK
    Hayward, NK
    Fountain, JW
    ONCOGENE, 1997, 15 (24) : 2999 - 3005
  • [37] Cdk4 and Cdk6 cooperate in counteracting the INK4 family of inhibitors during murine leukemogenesis
    Rodriguez-Diez, Esther
    Quereda, Victor
    Bellutti, Florian
    Prchal-Murphy, Michaela
    Partida, David
    Eguren, Manuel
    Kollmann, Karoline
    Gomez de Cedron, Marta
    Dubus, Pierre
    Canamero, Marta
    Martinez, Dolores
    Sexl, Veronika
    Malumbres, Marcos
    BLOOD, 2014, 124 (15) : 2380 - 2390
  • [38] c-JUN prevents methylation of p16INK4a (and Cdk6): the villain turned bodyguard
    Kollmann, Karoline
    Heller, Gerwin
    Sexl, Veronika
    ONCOTARGET, 2011, 2 (05) : 422 - 427
  • [39] PALBOCICLIB Cyclin CDK4/CDK6 Inhibitor Oncolytic
    Haddley, K.
    DRUGS OF THE FUTURE, 2013, 38 (11) : 745 - 755
  • [40] CDKN2a/p16INK4a mutations and lack of 0p19ARF involvement in familial melanoma kindreds
    Fargnoli, MC
    Chimenti, S
    Keller, G
    Soyer, HP
    Dal Pozzo, V
    Höfler, H
    Peris, K
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1998, 111 (06) : 1202 - 1206